Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Clinical trial NCT07001540 · RECRUITING
Trial details
- NCT number
- NCT07001540
- Sponsor
- Fudan University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-08
- Primary completion
- 2027-11-15
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.